Next Article in Journal
A Two-Year Follow-Up Cohort Study—Improved Clinical Control over CVD Risk Factors through Weight Loss in Middle-Aged and Older Adults
Previous Article in Journal
Resistance Exercise, Electrical Muscle Stimulation, and Whole-Body Vibration in Older Adults: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Perspective

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies

1
Intensive Care Unit, Ion Chiricuta Clinical Cancer Center, 400010 Cluj Napoca, Romania
2
Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400004 Cluj Napoca, Romania
3
Department of Anesthesia and Intensive Care, Iuliu Hatieganu University of Medicine and Pharmacy, 400000 Cluj Napoca, Romania
4
Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400000 Cluj Napoca, Romania
5
Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400014 Cluj Napoca, Romania
6
Department of Stem Cell Transplantation, Fundeni Clinical Institute, 925200 Bucharest, Romania
7
The Blood Bank, Landspitali–the National University Hospital of Iceland, Snorrabraut 60, 101 Reykjavik, Iceland
8
Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(9), 2903; https://doi.org/10.3390/jcm9092903
Received: 12 August 2020 / Revised: 21 August 2020 / Accepted: 1 September 2020 / Published: 8 September 2020
(This article belongs to the Section Hematology)
In the last decade there has been tremendous effort in offering better therapeutic management strategies to patients with hematologic malignancies. These efforts have ranged from biological to clinical approaches and resulted in the rapid development of new approaches. The main “problem” that comes with the high influx of newly approved drugs, which not only influences hematologists that frequently work with these drugs but also affects other healthcare professionals that work with hematologists in patient management, including intensive care unit (ICU) physicians, is they have to keep up within their specialty and, in addition, with the side-effects that can occur when encountering hematology-specific therapies. Nonetheless, there are few people that have an in-depth understanding of a specialty outside theirs. Thus, this manuscript offers an overview of the most common side-effects caused by therapies used in hematology nowadays, or that are currently being investigated in clinical trials, with the purpose to serve as an aid to other specialties. Nevertheless, because of the high amount of information on this subject, each chapter will offer an overview of the side-effects of a drug class with each reference of the section being intended as further reading. View Full-Text
Keywords: novel therapies; life-threatening side-effects; hematological malignancies novel therapies; life-threatening side-effects; hematological malignancies
Show Figures

Figure 1

MDPI and ACS Style

Constantinescu, C.; Pasca, S.; Zimta, A.-A.; Tat, T.; Rus, I.; Teodorescu, P.; Iluta, S.; Tanase, A.; Colita, A.; Sigurjonsson, O.; Einsele, H.; Tomuleasa, C. Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies. J. Clin. Med. 2020, 9, 2903. https://doi.org/10.3390/jcm9092903

AMA Style

Constantinescu C, Pasca S, Zimta A-A, Tat T, Rus I, Teodorescu P, Iluta S, Tanase A, Colita A, Sigurjonsson O, Einsele H, Tomuleasa C. Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies. Journal of Clinical Medicine. 2020; 9(9):2903. https://doi.org/10.3390/jcm9092903

Chicago/Turabian Style

Constantinescu, Catalin, Sergiu Pasca, Alina-Andreea Zimta, Tiberiu Tat, Ioana Rus, Patric Teodorescu, Sabina Iluta, Alina Tanase, Anca Colita, Olafur Sigurjonsson, Hermann Einsele, and Ciprian Tomuleasa. 2020. "Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies" Journal of Clinical Medicine 9, no. 9: 2903. https://doi.org/10.3390/jcm9092903

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop